CD4 and HIV-1 infection: As stated above, we find that daily dosing of uninfected CD4 T cells with AS1842856 results in much more complete CD62L down-modulation than the single dose we employed to assist HIV-1 infection (unpublished findings), consistent with the long half-life of CD62L mRNA and with the proposed mechanism of AS1842856 action [78].